ADAMTS4 and its proteolytic fragments differentially affect melanoma growth and angiogenesis in mice

International Journal of Cancer

Volumn 133, Issue 2, 2013, Pages 294-306

  Rao, Nithya ^a   Ke, Zhiyuan ^a   Liu, Hongrui ^b   Ho, Chao Jin ^a   Kumar, Saran ^a   Xiang, Wei ^a   Zhu, Yizhun ^b   Ge, Ruowen ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b FUDAN UNIVERSITY   (China)

Author keywords

ADAMTS4; angiogenesis; metalloproteinase; TSR; tumorigenesis

Indexed keywords

AGGRECANASE 1;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOMA; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; TUMOR PROMOTION; TUMOR VASCULARIZATION;

ADAM PROTEINS; AMINO ACID MOTIFS; ANIMALS; APOPTOSIS; CATALYSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PROCOLLAGEN N-ENDOPEPTIDASE; PROTEIN ISOFORMS; SKIN NEOPLASMS;

EID: 84877809602     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28037     Document Type: Article

References (35)

1. Porter S, Clark IM, Kevorkian L, et al. The ADAMTS metalloproteinases. Biochem J 2005; 386: 15-27.
2. Apte SS,. A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J Biol Chem 2009; 284: 31493-7.
3. Iruela-Arispe ML, Vazquez F, Ortega MA,. Antiangiogenic domains shared by thrombospondins and metallospondins, a new family of angiogenic inhibitors. Ann N Y Acad Sci 1999; 886: 58-66.
4. Vazquez F, Hastings G, Ortega MA, et al. METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem 1999; 274: 23349-57.
5. Dubail J, Kesteloot F, Deroanne C, et al. ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity. Cell Mol Life Sci 2010; 67: 4213-32.
6. Hsu YP, Staton CA, Cross N, et al. Anti-angiogenic properties of ADAMTS-4 in vitro. Int J Exp Pathol 2012; 93: 70-7.
7. Sharghi-Namini S, Fan H, Sulochana K, et al. The first but not the second thrombospondin type 1 repeat of ADAMTS5 functions as an angiogenesis inhibitor. Biochem Biophys Res Commun 2008; 371: 215-9.
8. Kumar S, Sharghi-Namini S, Rao N, et al. ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. Am J Pathol 2012; 181: 1056-68.
9. Koo B-H, Coe D, Dixon L, et al. ADAMTS9 is a cell-autonomously acting, anti-angiogenic metalloprotease expressed by microvascular endothelial cells. Am J Pathol 2010; 176: 1494-504.
10. Llamazares M, Obaya A, Moncada-Pazos A, et al. The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 2007; 120: 3544-52.
11. Nagase H, Kashiwagi M,. Aggrecanases and cartilage matrix degradation. Arthritis Res Ther 2003; 5: 94-103.
12. Stanton H, Rogerson F, East C, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005; 434: 648-700.
13. Glasson SS, Askew R, Sheppard B, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 2004; 50: 2547-58.
14. Wang P, Tortorella M, England K, et al. Proprotein convertase furin interacts with and cleaves pro-ADAMTS4 (Aggrecanase-1) in the trans-Golgi network. J Biol Chem 2004; 279: 15434-40.
15. Flannery C, Zeng W, Corcoran C, et al. Autocatalytic cleavage of ADAMTS-4 (Aggrecanase-1) reveals multiple glycosaminoglycan-binding sites. J Biol Chem 2002; 277: 42775-80.
16. Gao G, Plaas A, Thompson V, et al. ADAMTS4 (aggrecanase-1) activation on the cell surface involves C-terminal cleavage by glycosylphosphatidyl inositol-anchored membrane type 4-matrix metalloproteinase and binding of the activated proteinase to chondroitin sulfate and heparan sulfate on syndecan-1. J Biol Chem 2004; 279: 10042-51.
17. Held-Feindt J, Paredes EB, Blomer U, et al. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 2006; 118: 55-61.
18. Minobe K, Ono R, Matsumine A, et al. Expression of ADAMTS4 in Ewing's sarcoma. Int J Oncol 2010; 37: 569-81.
19. Wesley UV, Albino AP, Tiwari S, et al. A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 1999; 190: 311-22.
20. Tortorella M, Burn T, Pratta M, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (New York, N.Y.) 1999; 284: 1664-6.
21. Tortorella M, Pratta M, Liu R, et al. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000; 275: 18566-73.
22. Tortorella MD, Malfait AM, Deccico C, et al. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9: 539-52.
23. Lo P, Lung H, Cheung A, et al. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res 2010; 70: 5567-76.
24. Obika M, Ogawa H, Takahashi K, et al. Tumor growth inhibitory effect of ADAMTS1 is accompanied by the inhibition of tumor angiogenesis. Cancer Sci 2012; 103: 1889-97.
25. Liu YJ, Xu Y, Yu Q,. Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 2006; 25: 2452-67.
26. Kuno K, Bannai K, Hakozaki M, et al. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 2004; 319: 1327-33.
27. Ricciardelli C, Frewin K, Tan I, et al. The ADAMTS1 protease gene is required for mammary tumor growth and metastasis. Am J Pathol 2011; 179: 3075-85.
28. Luque A, Carpizo DR, Iruela-Arispe ML,. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003; 278: 23656-65.
29. Rodriguez-Manzaneque JC, Milchanowski AB, Dufour EK, et al. Characterization of METH-1/ADAMTS1 processing reveals two distinct active forms. J Biol Chem 2000; 275: 33471-9.
30. Galiano RD, Zhao LL, Clemmons DR, et al. Interaction between the insulin-like growth factor family and the integrin receptor family in tissue repair processes. Evidence in a rabbit ear dermal ulcer model. J Clin Investig 1996; 98: 2462-8.
31. Voronov E, Shouval D, Krelin Y, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 2003; 100: 2645-50.
32. Adini A, Kornaga T, Firoozbakht F, et al. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res 2002; 62: 2749-52.
33. Houghton A, Albino A, Cordon-Cardo C, et al. Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation. J Exp Med 1988; 167: 197-212.
34. Stecca B, Nardo B, Chieco P, et al. Aberrant dipeptidyl peptidase IV (DPP IV/CD26) expression in human hepatocellular carcinoma. J Hepatol 1997; 27: 337-45.
35. Huang SY, Xie KP, Bucana CD, et al. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells: Potential inhibition of angiogenesis. Clin Cancer Res 1996; 2: 1969-79.